Showing results (151-160 of 530) with videos related to
Sort By:
Pageof 53
Plos Medicine|September 16, 2024
Correction: Oncogenic Transformation by Inhibitor-Sensitive and -Resistant EGFR MutantsHeidi Greulich, Tzu-Hsiu Chen, Whei Feng, et al.Journal of the National Cancer Institute|March 8, 2020
Putting the Pieces Together: Completing the Mechanism of Action Jigsaw for Sipuleucel-TRavi A Madan, Emmanuel S Antonarakis, Charles G Drake, et al.Plos Medicine|September 29, 2005
Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutantsHeidi Greulich, Tzu-Hsiu Chen, Whei Feng, et al.Biorxiv : the Preprint Server for Biology|November 18, 2024
Dominant-negative TP53 mutations potentiated by the HSF1-regulated proteostasis networkRebecca M Sebastian, Jessica E Patrick, Tiffani Hui, et al.Advances in Urology|January 3, 2014
Pathologic Response Rates of Gemcitabine/Cisplatin versus Methotrexate/Vinblastine/Adriamycin/Cisplatin Neoadjuvant Chemotherapy for Muscle Invasive Urothelial Bladder CancerFranklin C Lee, William Harris, Heather H Cheng, et al.Cancer Research|March 19, 2009
PME-1 protects extracellular signal-regulated kinase pathway activity from protein phosphatase 2A-mediated inactivation in human malignant gliomaPietri Puustinen, Melissa R Junttila, Sari Vanhatupa, et al.Plos One|June 6, 2024
Correction: The SIRT1 Deacetylase Suppresses Intestinal Tumorigenesis and Colon Cancer GrowthRon Firestein, Gil Blander, Shaday Michan, et al.Urology|May 5, 2011
Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancerEvan Y Yu, Christophe Massard, Mitchell E Gross, et al.The Prostate|March 14, 2019
Clinical determinants for successful circulating tumor DNA analysis in prostate cancerMichael T Schweizer, Roman Gulati, Mallory Beightol, et al.Plos One|April 17, 2008
The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growthRon Firestein, Gil Blander, Shaday Michan, et al.Pageof 53